Literature DB >> 21358042

The role of osteopontin in neurodegenerative diseases.

Miryam Carecchio1, Cristoforo Comi.   

Abstract

Osteopontin (OPN) was shown to be involved in inflammatory and degenerative processes of the nervous system. In multiple sclerosis, the role of OPN has been studied in the inflammatory phase, where it was shown that the protein levels increase during disease relapses. Moreover, it was shown that subjects who carry a genotype associated with decreased protein levels tend to display a benign course. Taken altogether, these findings suggest that OPN may play a detrimental role in multiple sclerosis, at least in the inflammatory phase. In common neurodegenerative diseases, such as Parkinson's and Alzheimer's disease, OPN seems to act as a double-edged sword triggering neuronal toxicity and death in some contexts and functioning as a neuroprotectant in others. The involvement of OPN in several biological pathways and networks calls for more extensive research in order to unravel its role in the different disease phases and its potential as a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21358042     DOI: 10.3233/JAD-2011-102151

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  38 in total

Review 1.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

2.  Subtype-specific regeneration of retinal ganglion cells following axotomy: effects of osteopontin and mTOR signaling.

Authors:  Xin Duan; Mu Qiao; Fengfeng Bei; In-Jung Kim; Zhigang He; Joshua R Sanes
Journal:  Neuron       Date:  2015-03-05       Impact factor: 17.173

3.  Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.

Authors:  Min Shi; James Movius; Romel Dator; Patrick Aro; Yanchun Zhao; Catherine Pan; Xiangmin Lin; Theo K Bammler; Tessandra Stewart; Cyrus P Zabetian; Elaine R Peskind; Shu-Ching Hu; Joseph F Quinn; Douglas R Galasko; Jing Zhang
Journal:  Mol Cell Proteomics       Date:  2015-01-02       Impact factor: 5.911

Review 4.  The role of osteopontin in kidney diseases.

Authors:  Beata Kaleta
Journal:  Inflamm Res       Date:  2018-11-19       Impact factor: 4.575

5.  Evaluation of osteopontin as a potential biomarker for central nervous system embryonal tumors.

Authors:  Yi-Peng Han; Chen-Kai Ma; Shen-Qi Wang; Atsushi Enomoto; Yang Zhao; Masahide Takahashi; Jie Ma
Journal:  J Neurooncol       Date:  2014-05-31       Impact factor: 4.130

6.  The inflammatory response in acyl-CoA oxidase 1 deficiency (pseudoneonatal adrenoleukodystrophy).

Authors:  H I El Hajj; A Vluggens; P Andreoletti; K Ragot; S Mandard; S Kersten; H R Waterham; G Lizard; R J A Wanders; J K Reddy; Mustapha Cherkaoui-Malki
Journal:  Endocrinology       Date:  2012-04-16       Impact factor: 4.736

Review 7.  Inflammatory cytokines: potential biomarkers of immunologic dysfunction in autism spectrum disorders.

Authors:  Ningan Xu; Xiaohong Li; Yan Zhong
Journal:  Mediators Inflamm       Date:  2015-02-01       Impact factor: 4.711

8.  The impact of osteopontin gene variations on multiple sclerosis development and progression.

Authors:  Cristoforo Comi; Giuseppe Cappellano; Annalisa Chiocchetti; Elisabetta Orilieri; Sara Buttini; Laura Ghezzi; Daniela Galimberti; Franca Guerini; Nadia Barizzone; Franco Perla; Maurizio Leone; Sandra D'Alfonso; Domenico Caputo; Elio Scarpini; Roberto Cantello; Umberto Dianzani
Journal:  Clin Dev Immunol       Date:  2012-09-11

9.  Elevated osteopontin levels in mild cognitive impairment and Alzheimer's disease.

Authors:  Yuan Sun; Xue Song Yin; Hong Guo; Rong Kun Han; Rui Dong He; Li Jun Chi
Journal:  Mediators Inflamm       Date:  2013-03-14       Impact factor: 4.711

Review 10.  Role of osteopontin in systemic lupus erythematosus.

Authors:  Beata Kaleta
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-06-11       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.